home / stock / tptx / tptx news

TPTX News and Press, Turning Point Therapeutics Inc. From 10/07/21

Stock Information
Company Name: Turning Point Therapeutics Inc.
Stock Symbol: TPTX
Market: NYSE
Website: tptherapeutics.com
Menu
TPTX TPTX Quote TPTX Short TPTX News TPTX Articles TPTX Message Board
Get TPTX Alerts

News, Short Squeeze, Breakout and More Instantly...
TPTX - Merus, Nutriband leads healthcare gainers; Osmotica Pharmaceuticals, Prelude Therapeutics among major losers

Gainers: Merus (NASDAQ:MRUS) +36%, Nutriband (OTCQB:NTRB) +16%, Skylight Health (NASDAQ:SLHG) +16%, Rani Therapeutics (NASDAQ:RANI) +12%, Jupiter Wellness (NASDAQ:JUPW) +12%. Losers: Osmotica Pharmaceuticals (NASDAQ:OSMT) -38%, Prelude Therapeutics (NAS...
TPTX - Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates

Repotrectinib Demonstrates Clinical Activity Across Multiple ROS1+ TKI-Pretreated NSCLC Cohorts, with Confirmed Objective Response Rates of 30-39 Percent in TRIDENT-1 Study Repotrectinib Demonstrates Confirmed Objective Response Rate of 53 Percent in ROS1+ TKI-Pretreat...

TPTX - Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors

SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug Administration (FDA) granted a seventh regulatory des...

TPTX - Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference

SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced additional details for its data presentations, including a late-breaking pl...
TPTX - Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced a late-breaker abstract of early clinical data by physician assessment for ...

TPTX - Turning Point Therapeutics to Participate In Upcoming Investor Conferences

SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the ...

TPTX - DGE's 2nd Clinical Trial Agreements Conference to Negotiate Budgetary Restraints, Reduce Risks, and More in an Evolving Landscape

Date: September 16-17, 2021 Online Livestream Event – Locations will vary Dynamic Global Events (“DGE”) invites biopharma and medical device industry professionals to join them online September 16-17, 2021, for the 2nd Clinical Trial Agreements Conference. DGE&#x...
TPTX - Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors

SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced initiation of the first cohort of its Phase 1b/2 TRIDENT-2 combination study...

TPTX - Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib

SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug Administration (FDA) granted a sixth regulatory desig...

TPTX - Hot Stocks: SQSP, OSH drop on earnings news, TPTX climbs; KSU gets new bid; FULC more than doubles

Earnings news remained a key theme during Tuesday's midday trading. Squarespace (NYSE:SQSP) and Oak Street Health (NYSE:OSH) both dropped following the release of their quarterly updates. Meanwhile, Turning Point Therapeutics (NASDAQ:TPTX) got a boost after it reported better-than-expected re...
Previous 10 Next 10